Page 29 - Read Online

Page 319 Guerra et al. J Transl Genet Genom 2022;6:304-21 https://dx.doi.org/10.20517/jtgg.2022.08

18. Gantois I, Fang K, Jiang L, et al. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia,
hyperactivity, and impaired oral behavior. Proc Natl Acad Sci USA 2007;104:4182-7. DOI PubMed PMC
19. Park HY, Kim Y, Oh HM, Kim TW, Park GY, Im S. Potential prognostic impact of dopamine receptor d1 (. rs4532 ;12:675060. DOI
PubMed PMC
20. Nimmons D, Pendleton N, Payton A, et al. A novel association between COMT and BDNF gene polymorphisms and likelihood of
symptomatic dysphagia in older people. Neurogastroenterol Motil 2015;27:1223-31. DOI PubMed
21. Warnecke T, Oelenberg S, Teismann I, et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in
progressive supranuclear palsy. Mov Disord 2010;25:1239-45. DOI PubMed
22. Warnecke T, Suttrup I, Schröder JB, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability
testing of the FEES-Levodopa-test. Parkinsonism Relat Disord 2016;28:100-6. DOI PubMed
23. Hunter PC, Crameri J, Austin S, Woodward MC, Hughes AJ. Response of parkinsonian swallowing dysfunction to dopaminergic
stimulation. J Neurol Neurosurg Psychiatry 1997;63:579-83. DOI PubMed PMC
24. Hirano M, Isono C, Sakamoto H, Ueno S, Kusunoki S, Nakamura Y. Rotigotine transdermal patch improves swallowing in dysphagic
patients with parkinson’s disease. Dysphagia 2015;30:452-6. DOI PubMed
25. Hirano M, Isono C, Fukuda K, Ueno S, Nakamura Y, Kusunoki S. Effects of the rotigotine transdermal patch versus oral levodopa on
swallowing in patients with Parkinson’s disease. J Neurol Sci 2019;404:5-10. DOI PubMed
26. Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in
Parkinson’s disease. Mov Disord 1996;11:729-32. DOI PubMed
27. Michou E, Hamdy S, Harris M, et al. Characterization of corticobulbar pharyngeal neurophysiology in dysphagic patients with
Parkinson’s disease. Clin Gastroenterol Hepatol 2014;12:2037-45.e1. DOI PubMed
28. Chang MC, Park JS, Lee BJ, Park D. Effectiveness of pharmacologic treatment for dysphagia in Parkinson’s disease: a narrative
review. Neurol Sci 2021;42:513-9. DOI PubMed
29. Kobayashi H, Nakagawa T, Sekizawa K, Arai H, Sasaki H. Levodopa and swallowing reflex. Lancet 1996;348:1320-1. DOI PubMed
30. Arai T, Sekizawa K, Yoshimi N, Toshima S, Fujiwara H. Cabergoline and silent aspiration in elderly patients with stroke. J Am
Geriatr Soc 2003;51:1815-6. DOI PubMed
31. Nakagawa T, Wada H, Sekizawa K, Arai H, Sasaki H. Amantadine and pneumonia. Lancet 1999;353:1157. DOI PubMed
32. Apaydin H, Ertan S, Ozekmekçi S. Broad bean (Vicia faba) - A natural source ofL-dopa-Prolongs “on” periods in patients with
Parkinson’s disease who have “on-off” fluctuations. Mov Disord 2000;15:164-6. DOI
33. Kanazawa K, Sakakibara H. High content of dopamine, a strong antioxidant, in Cavendish banana. J Agric Food Chem 2000;48:844-8.
DOI PubMed
34. Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. Sci Rep 2015;5:11078. DOI
PubMed PMC
35. Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological
study. J Neurol Neurosurg Psychiatry 2004;75:1672-7. DOI PubMed PMC
36. Cacabelos R, Carrera I, Martínez O, et al. Atremorine in parkinson’s disease: from dopaminergic neuroprotection to
pharmacogenomics. Med Res Rev 2021;41:2841-86. DOI PubMed
37. Cacabelos R. World guide for drug use and pharmacogenomics. Corunna, Spain: EuroEspes Publishing Co., 2012.
38. Soler-Alfonso C, Motil KJ, Turk CL, et al. Potocki-Lupski syndrome: a microduplication syndrome associated with oropharyngeal
dysphagia and failure to thrive. J Pediatr 2011;158:655-659.e2. DOI PubMed PMC
39. Michałowska M, Chalimoniuk M, Jówko E, et al. Gene polymorphisms and motor levodopa-induced complications in Parkinson’s
disease. Brain Behav 2020;10:e01537. DOI PubMed PMC
40. Zhao C, Wang Y, Zhang B, Yue Y, Zhang J. Genetic variations in catechol-O-methyltransferase gene are associated with levodopa
response variability in Chinese patients with Parkinson’s disease. Sci Rep 2020;10:9521. DOI PubMed PMC
41. Rieck M, Schumacher-Schuh AF, Callegari-Jacques SM, et al. Is there a role for ADORA2A polymorphisms in levodopa-induced
dyskinesia in Parkinson’s disease patients? Pharmacogenomics 2015;16:573-82. DOI PubMed
42. Schumacher-Schuh AF, Altmann V, Rieck M, et al. Association of common genetic variants of HOMER1 gene with levodopa adverse
effects in Parkinson’s disease patients. Pharmacogenomics J 2014;14:289-94. DOI PubMed
43. Rieck M, Schumacher-Schuh AF, Altmann V, et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in
Parkinson’s disease patients. Pharmacogenomics 2012;13:1701-10. DOI PubMed
44. Moreau C, Meguig S, Corvol JC, et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in
Parkinson’s disease. Brain 2015;138:1271-83. DOI PubMed PMC
45. Ahmed SS, Husain RS, Kumar S, Ramakrishnan V. Association between MDR1 gene polymorphisms and Parkinson’s disease in
Asian and Caucasian populations: a meta-analysis. J Neurol Sci 2016;368:255-62. DOI PubMed
46. Lohr KM, Masoud ST, Salahpour A, Miller GW. Membrane transporters as mediators of synaptic dopamine dynamics: implications
for disease. Eur J Neurosci 2017;45:20-33. DOI PubMed PMC
47. Pouget JG, Shams TA, Tiwari AK, Müller DJ. Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci
2014;16:555-66. PubMed PMC
48. Yoshida K, Müller DJ. Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol Neuropsychiatry
2020;5:1-26. DOI PubMed PMC